US IPO Market In 2022 Even Underperformed Normal Years

Outlier Kept Average Return In The Black

 
• By Mandy Jackson

INFOGRAPHIC: The number of biopharma offerings in 2022 was far below records set in 2020 and 2021, but also below more normal years of 2018 and 2019. The IPO class of 2022 eked out a positive average return, however.  

Words IPO (Initial public offering) with the trading data on the background
22 drug developers went public in the US in 2022 raising $2.5bn • Source: Shutterstock

More from Financing

More from Business